# OnCo record sillajen (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sillajen/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sillajen" ;
  schema:name "SillaJen"@en ;
  schema:alternateName "SillaJen, Inc."@en, "SillaJen Inc."@en, "SillaJen Biotherapeutics"@en ;
  schema:description "SillaJen is a South Korean company that began with viruses engineered to infect and kill cancer cells. Its newest medicine, BAL0891, is a tablet-type drug that blocks two enzymes cancer cells need to divide, and the FDA gave it orphan drug status for acute myeloid leukaemia in 2026."@en ;
  schema:url <https://onco.cc/companies/sillajen/>, <https://www.sillajen.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.sillajen.com/>, <https://www.sillajen.com/eng/sub/pipeline_bal0891.html>, <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1162426>, <https://clinicaltrials.gov/study/NCT05768932> ;
  schema:addressCountry "KR" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ttk/>, <https://onco.cc/targets/plk1/> ;
  onco:drugs <https://onco.cc/drugs/bal0891/> .